Skip to main content

NABP weighs in on medication importation from Canada


The National Association of Boards of Pharmacy is calling for more carefully study of the safety implications of allowing importation of prescription drugs from Canada after the Trump Administration announced plans on Sept. 24 as part of the "America First Healthcare Plan," to allow this practice.

In a letter to its members, the state boards of pharmacy, NABP cautioned that allowing such practices places American patients at risk.

NABP said that it appreciates these efforts to increase patient access to affordable medications, but added that assurances that patients receive safe medication are vital.

As the actual benefit and savings of the prescription drug importation plans are unknown, NABP said it encourages state and federal regulators to study this issue more carefully prior to placing American patients and the prescription drug supply chain at risk.

Counterfeit drugs sales are lucrative, generating over $200 billion a year in profit for global criminal networks. The new importation plans open additional points of vulnerability in the United States prescription drug supply chain, specifically, a patchwork approach that is a step away from the tightly regulated supply chain and safeguards currently in place to ensure the efficacy and safety of prescription medications, NABP said.

The National Association of Pharmacy Regulatory Authorities, NABP’s counterpart in Canada, has expressed concern that exportation of medicines out of Canada will threaten the supply available to its citizens. This, in turn, will increase the opportunity for counterfeit medications to enter its supply chain, endangering both U.S. and Canadian patients, said NABP.

NABP also is concerned that encouraging prescription drug importation will lead to the proliferation of rogue online pharmacy websites that will undoubtedly purport to be authorized to import medications from foreign countries. Rogue pharmacy networks are opportunistic and will look for any opportunity to prey on vulnerable patients. The May 2020 Rogue Rx Activity Report details the trends NABP identified during the coronavirus disease 2019 pandemic.

NABP is the only not-for-profit professional association that represents the boards of pharmacy in all 50 United States, the District of Columbia, Guam, Puerto Rico, the Virgin Islands, the Bahamas, and all 10 Canadian provinces. Its member boards of pharmacy are responsible for ensuring the safety of the prescription drug supply chain and the products in it.


This ad will auto-close in 10 seconds